Literature DB >> 9366318

Intravesical capsaicin as a treatment for refractory detrusor hyperreflexia: a dual center study with long-term followup.

D De Ridder1, V Chandiramani, P Dasgupta, H Van Poppel, L Baert, C J Fowler.   

Abstract

PURPOSE: We described the long-term outcome of intravesical capsaicin instillations in patients with urinary incontinence and compared its efficacy in 2 similar populations of patients with multiple sclerosis in a dual center study.
MATERIALS AND METHODS: During 5 years 79 patients with intractable urinary incontinence have been treated with intravesical capsaicin. The majority of patients had spinal cord disease due to multiple sclerosis but 4 were neurologically normal. Cystometry was performed before and 4 to 6 weeks after intravesical instillation of 1 to 2 mmol./l. of capsaicin in 30% ethanol in saline. Instillations of vehicle (30% ethanol in saline) alone were carried out in 5 patients.
RESULTS: In patients with phasic detrusor hyperreflexia complete continence was achieved in 44%, satisfactory improvement occurred in 36% and treatment failed in 20%. Clinical benefit from a single instillation lasted 3 to 6 months and was repeated in some patients with similar improvement. Capsaicin was ineffective in patients with poor bladder compliance and in neurologically normal patients with sensory urgency and detrusor instability. There was no clinical or urodynamic improvement in patients treated with vehicle alone. There have been no long-term complications.
CONCLUSIONS: Our study shows that repeated instillations of intravesical capsaicin are effective in treatment of patients with detrusor hyperreflexia due to spinal cord disease and that effectiveness of the treatment persists at least 3 to 5 years.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9366318     DOI: 10.1016/s0022-5347(01)68162-x

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  16 in total

Review 1.  Management of secondary-progressive multiple sclerosis.

Authors:  Gavin Giovannoni
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

2.  Is sensory urgency part of the same spectrum of bladder dysfunction as detrusor overactivity?

Authors:  Bernard T Haylen; Naven Chetty; Vanessa Logan; Serena Schulz; Louise Verity; Matthew Law; Jialun Zhou
Journal:  Int Urogynecol J Pelvic Floor Dysfunct       Date:  2006-07-06

Review 3.  TRPV1 (vanilloid receptor) in the urinary tract: expression, function and clinical applications.

Authors:  António Avelino; Francisco Cruz
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2006-05-24       Impact factor: 3.000

4.  The overactive bladder.

Authors:  Richard Foon; Marcus J Drake
Journal:  Ther Adv Urol       Date:  2010-08

Review 5.  TRP channels in lower urinary tract dysfunction.

Authors:  J Franken; P Uvin; D De Ridder; T Voets
Journal:  Br J Pharmacol       Date:  2014-05       Impact factor: 8.739

6.  The future of bladder control-intravesical drug delivery, a pinch of pepper, and gene therapy.

Authors:  Matthew O Fraser; John P Lavelle; Michael S Sacks; Michael B Chancellor
Journal:  Rev Urol       Date:  2002

7.  Intravesical instillation of botulinum toxin A: an in vivo murine study and pilot clinical trial.

Authors:  Jan Krhut; Peter Zvara
Journal:  Int Urol Nephrol       Date:  2010-06-20       Impact factor: 2.370

Review 8.  Desensitization of bladder sensory fibers by intravesical capsaicin or capsaicin analogs. A new strategy for treatment of urge incontinence in patients with spinal detrusor hyperreflexia or bladder hypersensitivity disorders.

Authors:  F Cruz
Journal:  Int Urogynecol J Pelvic Floor Dysfunct       Date:  1998

9.  Overactive bladder: pharmacologic treatments in the neurogenic population.

Authors:  Michael J Kennelly; William B Devoe
Journal:  Rev Urol       Date:  2008

10.  TRPV1: a target for next generation analgesics.

Authors:  Louis S Premkumar; Parul Sikand
Journal:  Curr Neuropharmacol       Date:  2008-06       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.